Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GlaxoSmithKline. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

 

FY2020-2024 figures are as at 29/05/2020

Please select...
£m (unless stated) 2020 2021 2022 2023 2024 2020-2024 n=
Turnover 35,352 36,549 37,899 39,273 41,023 13
Cost of sales (10,445) (10,723) (11,040) (11,358) (11,800) 13
Selling, general and administration (11,164) (11,328) (11,519) (11,745) (12,039) 13
Research and Development (4,778) (5,172) (5,388) (5,555) (5,751) 13
Royalty income 309 316 334 347 226 13
Operating profit 9,274 9,643 10,285 10,962 11,658 13
Net finance costs (844) (814) (783) (743) (712) 13
Associates 32 53 30 30 30 13
Profit before tax 8,463 8,882 9,532 10,249 10,977 13
Taxation (1,420) (1,616) (1,795) (1,949) (2,089) 13
Profit after tax  7,043 7,266 7,737 8,299 8,888 13
Minority interests (1,144) (1,212) (1,280) (1,328) (1,365) 13
Profit attributable to shareholders 5,899 6,054 6,457 6,971 7,523 13
WANS (m) 4,972 4,990 5,009 5,028 5,039 13
Earnings per share (p) 118.6 121.3 128.9 138.7 149.3 13
Dividend per share (p) 80.0 80.1 80.7 81.6 82.9 12
Free Cash Flow 4,604 5,185 5,953 6,755 7,149 10
Net Debt (23,399) (22,452) (21,096) (18,976) (16,664) 12

The firms included are: Bank of America, Barclays, Citi, Credit
Suisse, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, SVB Leerink, UBS, Wolfe Research

Turnover £m 2020 2021 2022 2023 2024 2020-2024 n=
Anoro 554 592 621 645 665 13
Arnuity 53 56 58 59 59 13
Incruse 259 275 288 299 311 13
Relvar/Breo 993 1,003 1,021 1,032 1,043 13
Trelegy 853 1,144 1,382 1,579 1,738 13
Ellipta portfolio 2,713 3,071 3,370 3,614 3,817 13
Nucala 925 1,036 1,122 1,191 1,247 13
Total Respiratory 3,637 4,106 4,492 4,806 5,064 13
             
Tivicay 1,624 1,569 1,509 1,445 1,388 11
Triumeq 2,321 2,151 2,019 1,911 1,812 11
Juluca 520 629 701 750 770 13
Dovato 301 551 805 1,003 1,163 13
Dolutegravir based regimens 4,763 4,887 5,005 5,062 5,065 13
Cabotegravir +/- rilpivirine 4 98 225 361 499 13
fostemsavir 18 86 144 196 235 10
Epzicom/Kivexa 44 34 27 23 19 13
HIV 4,947 5,188 5,454 5,676 5,845 13
             
Benylsta 727 818 890 945 972 13
             
Zejula 390 563 741 896 1,032 13
             
Advair (US) 312 213 170 142 127 13
Seretide (ex US) 1,086 961 870 797 739 13
Seretide/Advair 1,397 1,174 1,040 939 865 13
Flixotide/Flovent 551 522 497 474 452 13
Ventolin 797 717 684 658 635 13
Avamys/Veramyst 324 327 326 291 272 12
Established Respiratory 3,327 2,991 2,788 2,595 2,451 13
Other Established Pharmaceuticals 4,544 4,287 4,074 3,865 3,684 13
Established Pharmaceuticals 7,871 7,278 6,862 6,460 6,135 13
             
belantamab mafodotin (GSK'916 BCMA) 49 216 396 613 825 13
dostarlimab 22 78 148 228 296 10
daprodustat - 16 73 157 239 11
             
Pharmaceuticals 17,639 18,249 19,060 19,867 20,660 13

The firms included are: Bank of America, Barclays, Citi, Credit
Suisse, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, SVB Leerink, UBS, Wolfe Research

Turnover £m 2020 2021 2022 2023 2024 2020-2024 n=
Bexsero 729 787 829 862 890 12
Menveo 275 283 292 299 307 12
Fluarix/Flulaval 572 596 618 638 657 13
Shingrix 2,198 2,532 2,679 2,859 3,403 13
Boostrix 589 601 610 618 626 12
Cervarix 49 49 49 49 49 12
Hepatitis 780 811 831 849 864 12
Infanrix, Pediarix 718 720 724 728 734 12
Rotarix 568 580 592 603 615 12
Synflorix 468 470 468 464 457 12
Vaccines 7,440 7,933 8,205 8,496 9,165 13

The firms included are: Bank of America, Barclays, Citi, Credit
Suisse, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, SVB Leerink, UBS, Wolfe Research

Turnover £m 2020 2021 2022 2023 2024 2020-2024 n=
Oral Care 2,819 2,931 3,040 3,153 3,268 9
Pain Relief 2,144 2,222 2,298 2,374 2,454 8
Respiratory health 1,405 1,443 1,485 1,522 1,560 8
VMS 1,254 1,303 1,347 1,385 1,425 8
Digestive Health and other 1,852 1,911 1,967 2,022 2,074 8
Brands divested and under review 764 542 483 439 405 8
Consumer Health 10,241 10,354 10,620 10,897 11,184 13

The firms included are: Bank of America, Barclays, Citi, Credit
Suisse, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, SVB Leerink, UBS, Wolfe Research

Back to top